Newland Pharmaceutical Co., Ltd.

¥8.90As of Sun 8 Nov 2026, 12:00 UTC
SZSE:301277Healthcare
Country China
PE (Fwd) •••
TSR 4Y CAGR (4.22%)
Div yield 2.25%
ROE 5.98%
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.29
PE TTM 37.33
TSR TTM (31.33%)
Mkt cap ¥3.489B
ROIC 9.97%
SE Grade™
Value
Quality
Moat
Consensus
Reference
¥12
29.78%
(64.12%)
Hold 4|2|10|6|8
4Q25
1Q26
2Q26
3Q26
Earnings per share¥
0.18
0.18
0.17
0.17
20.54%
12.08%
7.73%
1.27%
Revenue¥M
163.5
168.6
174.6
175.2
1.95%
7.02%
11.94%
12.06%
Peers (US$523.1M)
Cap (US$)
PE
524.0M
31.37x
518.3M
27.02x
Capital
TTM
5Y
10Y
Leveragex
2.530
1.971
1.850
EBIT/Intx
0.396
0.050
0.059
Own earn%
(9.70)
(2.99)
1.70
Sh yield%
32.20
49.27
47.80
Owners
Insiders/Inst%
0.77
47.80
Short interest%
1.35
SBC / revenue%
4.27
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
8
Op margin range%
15–23
$1 testx
—
Incr. ROIC%
9